Physician profile
Roger Gaddy
NPI 1669495917
$5,113.34
in general payments reported to CMS, 2019-2025
45 companies · $659 in 2025
The $659 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $871 · 2021: $1,229 · 2022: $531 · 2023: $638 · 2024: $688 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $647.02 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $505.05 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $469.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Dexcom, INC. | $421.73 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $415.56 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $329.70 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $241.12 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $193.59 | 2019-2023 | |
| Glaxosmithkline, LLC. | $183.70 | 2019-2024 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $173.33 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $157.79 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.98 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $107.18 | 2022-2025 | Keveyis |
| Takeda Pharmaceuticals U.S.A., INC. | $88.58 | 2019-2022 | |
| Esperion Therapeutics, INC. | $80.96 | 2020-2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $74.34 | 2020-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Eisai INC. | $68.87 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $52.09 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.57 | 2025 | Xifaxan |
| Allergan, INC. | $43.64 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $43.35 | 2019-2021 | |
| Edwards Lifesciences Corporation | $43.21 | 2022 | |
| Grifols USA, LLC | $41.24 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.10 | 2025 | Caplyta |
| Optinose US, INC. | $38.16 | 2021 | |
| Genentech USA, INC. | $33.28 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $33.12 | 2020-2022 | |
| Vivus LLC | $31.28 | 2020-2021 | |
| Abbott Laboratories | $31.16 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $30.46 | 2021-2023 | |
| Recor Medical INC | $29.22 | 2025 | Paradise Ultrasound Renal Denervation System |
| Insulet Corporation | $26.34 | 2023 | Omnipod |
| Nestle Healthcare Nutrition INC. | $26.26 | 2021 | |
| Abiomed | $24.85 | 2025 | |
| Acadia Pharmaceuticals INC | $20.87 | 2025 | Nuplazid |
| Lundbeck LLC | $19.59 | 2022 | |
| Hologic Sales and Service, LLC | $19.15 | 2024 | Aptima, Thinprep 2000 Processor |
| Biohaven Pharmaceuticals, INC. | $18.17 | 2020 | |
| Exact Sciences Corporation | $17.52 | 2024 | Cologuard Collection Kit |
| Seqirus USA INC | $16.74 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Mylan Specialty L.P. | $16.57 | 2020 | |
| Stryker Corporation | $15.68 | 2025 | Clottriever Bold Catheter |
| Corcept Therapeutics | $15.44 | 2025 | Korlym |
| Medtronic USA, INC. | $14.79 | 2019 | |
| Astellas Pharma US INC | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Gaddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.